Review of 20 cases of advanced mucosal melanoma

January 1, 2025Skin CancerOpen Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

To evaluate overall survival and response rates in advanced mucosal melanoma treated with immunotherapies and targeted therapies.
Reviewed 20 cases of advanced mucosal melanoma treated since 2014.
Assessed the effectiveness of immune checkpoint inhibitors and BRAF/MEK inhibitors as first-line therapies.
Compared the outcomes of monotherapy with anti-PD-1 antibodies to combination therapy with anti-PD-1 and anti-CTLA-4 antibodies.
5-year survival rates for mucosal melanoma were lower compared to other melanoma types.
Combination therapy tended to show better effectiveness than monotherapy with anti-PD-1 antibodies.
Mucosal melanoma cases often lack BRAF mutations, leading to a preference for immune checkpoint inhibitor therapy.

This review analyzes the survival and response rates in patients with advanced mucosal melanoma, suggesting careful treatment choices are crucial.

No abstract yet. The journal hasn't published one we can show.

No takes yet. Share an insight, caveat, or question.

Ito et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share